Elutia Received FDA Clearance of EluPro
Portfolio Pulse from Benzinga Newsdesk
Elutia has received FDA clearance for EluPro, the only drug-eluting biologic envelope in the $600 million U.S. implantable electronic device protection market. EluPro is also cleared for use with neurostimulators and neuromodulators for various medical conditions.
June 17, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elutia's EluPro has received FDA clearance, making it the only drug-eluting biologic envelope in the $600 million U.S. implantable electronic device protection market. This clearance also extends to neurostimulators and neuromodulators for various medical conditions.
The FDA clearance of EluPro positions Elutia uniquely in a $600 million market, likely boosting its market share and revenue. The additional clearance for neurostimulators and neuromodulators further expands its potential market, making this a significant positive development for the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100